[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-001", "question": "A 45-year-old with severe ARDS on VV-ECMO develops suspected heparin-induced thrombocytopenia (4T score 6). Heparin is discontinued and argatroban initiated. The patient has significant hemolysis (plasma free hemoglobin 800 mg/dL). Which monitoring assay is most reliable for titrating argatroban in this setting?", "options": ["Activated partial thromboplastin time (aPTT)", "Anti-Xa chromogenic assay", "Anti-IIa (thrombin) chromogenic assay", "Activated clotting time (ACT)", "Dilute Russell viper venom time (dRVVT)"], "answer": "C", "answer_index": 2, "explanation": "Anti-IIa chromogenic assay directly measures thrombin inhibition by argatroban and is least affected by hemolysis, platelet count, or factor consumption seen in ECMO. aPTT is unreliable due to factor deficiency and hemolysis. Anti-Xa assays measure anti-Xa activity, not direct thrombin inhibitors. ACT is affected by platelets and fibrinogen. dRVVT is used for lupus anticoagulant detection.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The question asks for the most reliable monitoring method for Argatroban (a Direct Thrombin Inhibitor) in a complex patient (ECMO, HIT, hemolysis). Option A (aPTT) is the standard initial test but is notoriously unreliable in ECMO patients due to factor consumption, acute phase reactants, and potential baseline coagulopathy; it is also non-linear at high doses. Option B (Anti-Xa) targets Factor Xa inhibitors (heparin, LMWH, apixaban), not DTIs. Option D (ACT) is non-specific and influenced by platelets and fibrinogen. Option E (dRVVT) is a diagnostic test for lupus anticoagulant, not for drug monitoring. Option C (Anti-IIa chromogenic assay) specifically measures direct thrombin inhibition and correlates best with plasma drug concentrations, avoiding the biological confounding variables of the aPTT (factor levels, lupus anticoagulant). Although severe hemolysis (800 mg/dL) can technically interfere with optical readouts in chromogenic assays, it is the only option that targets the correct mechanism with high specificity. In the context of 'aPTT is unreliable,' the Anti-IIa assay is the standard board-exam answer for the alternative monitoring strategy. The item is logically sound and medically accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The question asks for the most reliable monitoring method for Argatroban (a Direct Thrombin Inhibitor) in a complex patient (ECMO, HIT, hemolysis). Option A (aPTT) is the standard initial test but is notoriously unreliable in ECMO patients due to factor consumption, acute phase reactants, and potential baseline coagulopathy; it is also non-linear at high doses. Option B (Anti-Xa) targets Factor Xa inhibitors (heparin, LMWH, apixaban), not DTIs. Option D (ACT) is non-specific and influenced by platelets and fibrinogen. Option E (dRVVT) is a diagnostic test for lupus anticoagulant, not for drug monitoring. Option C (Anti-IIa chromogenic assay) specifically measures direct thrombin inhibition and correlates best with plasma drug concentrations, avoiding the biological confounding variables of the aPTT (factor levels, lupus anticoagulant). Although severe hemolysis (800 mg/dL) can technically interfere with optical readouts in chromogenic assays, it is the only option that targets the correct mechanism with high specificity. In the context of 'aPTT is unreliable,' the Anti-IIa assay is the standard board-exam answer for the alternative monitoring strategy. The item is logically sound and medically accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-002", "question": "A 62-year-old with metastatic pancreatic adenocarcinoma on gemcitabine presents with acute kidney injury (creatinine 3.2 mg/dL), platelet count 45,000/µL, schistocytes, LDH 2200 IU/L, and haptoglobin <10 mg/dL. ADAMTS13 activity is 35%. What is the most appropriate initial management?", "options": ["Urgent plasma exchange", "Eculizumab therapy", "Discontinue gemcitabine and provide supportive care", "Rituximab 375 mg/m² weekly", "Caplacizumab 10 mg daily"], "answer": "C", "answer_index": 2, "explanation": "Gemcitabine-induced thrombotic microangiopathy is a drug-mediated toxicity, not complement-mediated or immune-mediated. ADAMTS13 is not severely deficient (<10%), excluding TTP. Plasma exchange is ineffective. Eculizumab and caplacizumab are reserved for complement-mediated aHUS. Rituximab is for TTP. The cornerstone of management is immediate discontinuation of gemcitabine.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette presents a classic case of gemcitabine-induced thrombotic microangiopathy (TMA) in a patient with pancreatic cancer. Key findings include microangiopathic hemolytic anemia (schistocytes, elevated LDH), thrombocytopenia, and acute kidney injury. Crucially, the ADAMTS13 activity of 35% rules out Thrombotic Thrombocytopenic Purpura (TTP), which is defined by activity <10%. This finding invalidates TTP-specific interventions such as plasma exchange (Option A), rituximab (Option D), and caplacizumab (Option E). It is worth noting the provided rationale incorrectly associates caplacizumab with aHUS (it is an anti-vWF agent for TTP), but this error does not impact the correct answer since TTP is excluded by the lab data. Gemcitabine-induced TMA is a form of drug-induced TMA (DITMA). The cornerstone of initial management is the immediate discontinuation of the drug (Option C). While eculizumab (Option B) is sometimes used in cases suspected to be complement-mediated or refractory to drug cessation, it is not the first-line step. The item correctly identifies drug discontinuation as the primary action. The question is logically valid, the distractors are effectively ruled out by the lab values, and the key represents the standard of care.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette presents a classic case of gemcitabine-induced thrombotic microangiopathy (TMA) in a patient with pancreatic cancer. Key findings include microangiopathic hemolytic anemia (schistocytes, elevated LDH), thrombocytopenia, and acute kidney injury. Crucially, the ADAMTS13 activity of 35% rules out Thrombotic Thrombocytopenic Purpura (TTP), which is defined by activity <10%. This finding invalidates TTP-specific interventions such as plasma exchange (Option A), rituximab (Option D), and caplacizumab (Option E). It is worth noting the provided rationale incorrectly associates caplacizumab with aHUS (it is an anti-vWF agent for TTP), but this error does not impact the correct answer since TTP is excluded by the lab data. Gemcitabine-induced TMA is a form of drug-induced TMA (DITMA). The cornerstone of initial management is the immediate discontinuation of the drug (Option C). While eculizumab (Option B) is sometimes used in cases suspected to be complement-mediated or refractory to drug cessation, it is not the first-line step. The item correctly identifies drug discontinuation as the primary action. The question is logically valid, the distractors are effectively ruled out by the lab values, and the key represents the standard of care.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-003", "question": "A 28-year-old presents 2 hours after ingesting barium carbonate with profuse vomiting, diarrhea, and profound muscle weakness. Serum potassium is 2.1 mEq/L with ST-segment depression on ECG. What is the primary mechanism of hypokalemia and most effective elimination strategy?", "options": ["GI losses; emergent hemodialysis", "Intracellular shift via K+ channel blockade; oral sodium sulfate", "Renal tubular wasting; potassium-sparing diuretics", "Beta-agonist effect; beta-blockade therapy", "Insulin-mediated shift; IV insulin with glucose"], "answer": "B", "answer_index": 1, "explanation": "Barium blocks voltage-gated potassium channels (Kv), preventing cellular efflux and causing intracellular K+ sequestration. Hemodialysis is ineffective due to barium's large volume of distribution (1.5 L/kg). Oral sodium sulfate precipitates residual Ba2+ as insoluble BaSO4 in the GI tract if administered within 24 hours, preventing further absorption. Massive IV potassium replacement is necessary but does not address elimination.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The item presents a classic case of acute barium toxicity (ingestion of soluble barium carbonate), characterized by gastrointestinal symptoms and profound hypokalemic paralysis. The mechanism of hypokalemia in barium toxicity is the blockade of potassium channels (specifically blocking passive K+ efflux while Na-K-ATPase continues), leading to a massive intracellular shift of potassium. This aligns perfectly with Option B. The specific decontamination strategy for soluble barium salts is the administration of a sulfate source (like sodium sulfate or magnesium sulfate) to precipitate the barium as insoluble barium sulfate in the GI tract, preventing further absorption. While hemodialysis is sometimes used in severe cases with renal failure, the classic specific elimination/decontamination strategy is sulfate precipitation. Option A is incorrect because the primary mechanism is a shift, not GI losses, and HD is not the first-line elimination strategy. Options C, D, and E cite incorrect mechanisms. The item is medically accurate and logically sound.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The item presents a classic case of acute barium toxicity (ingestion of soluble barium carbonate), characterized by gastrointestinal symptoms and profound hypokalemic paralysis. The mechanism of hypokalemia in barium toxicity is the blockade of potassium channels (specifically blocking passive K+ efflux while Na-K-ATPase continues), leading to a massive intracellular shift of potassium. This aligns perfectly with Option B. The specific decontamination strategy for soluble barium salts is the administration of a sulfate source (like sodium sulfate or magnesium sulfate) to precipitate the barium as insoluble barium sulfate in the GI tract, preventing further absorption. While hemodialysis is sometimes used in severe cases with renal failure, the classic specific elimination/decontamination strategy is sulfate precipitation. Option A is incorrect because the primary mechanism is a shift, not GI losses, and HD is not the first-line elimination strategy. Options C, D, and E cite incorrect mechanisms. The item is medically accurate and logically sound.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-004", "question": "A 3-month-old infant presents with intractable seizures, hypotonia, and developmental regression. Brain MRI shows bilateral globus pallidus hyperintensity. Plasma creatine level is low. Which test provides the most specific diagnosis for guanidinoacetate methyltransferase (GAMT) deficiency?", "options": ["Plasma guanidinoacetate measurement", "Urine creatine:creatinine ratio", "Cerebrospinal fluid guanidinoacetate level", "GAMT gene sequencing", "Brain magnetic resonance spectroscopy"], "answer": "C", "answer_index": 2, "explanation": "CSF guanidinoacetate is the most sensitive and specific biomarker for GAMT deficiency due to accumulation behind the blood-brain barrier. Plasma GAA can be normal in mild cases. Urine ratio is supportive but nonspecific. GAMT sequencing may miss deep intronic variants or large deletions. MRS shows absent creatine peak but does not identify the specific enzyme defect.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes a classic presentation of Guanidinoacetate Methyltransferase (GAMT) deficiency (intractable seizures, hypotonia, low plasma creatine, and globus pallidus hyperintensity). The standard diagnostic criteria for GAMT deficiency are elevated guanidinoacetate (GAA) in plasma or urine, followed by confirmation via molecular testing. The keyed answer (C, CSF guanidinoacetate) is incorrect as the 'most specific' or best diagnostic test. In untreated symptomatic infants, plasma GAA (Option A) is markedly elevated and is the standard non-invasive screening tool. Furthermore, if 'specificity' is the primary criterion, *GAMT* gene sequencing (Option D) is the gold standard for a specific diagnosis, providing molecular confirmation. The rationale's claim that plasma GAA can be normal in untreated cases contradicts standard medical literature (e.g., GeneReviews), and the emphasis on CSF suggests a confusion with Creatine Transporter Deficiency (SLC6A8), where systemic markers are often normal and CSF/brain levels are required for diagnosis. Because a superior, standard-of-care answer exists (D for specificity, A for screening) and the key relies on flawed medical reasoning, the item is miskeyed.\",\"medical_accuracy_score\":\"2\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes a classic presentation of Guanidinoacetate Methyltransferase (GAMT) deficiency (intractable seizures, hypotonia, low plasma creatine, and globus pallidus hyperintensity). The standard diagnostic criteria for GAMT deficiency are elevated guanidinoacetate (GAA) in plasma or urine, followed by confirmation via molecular testing. The keyed answer (C, CSF guanidinoacetate) is incorrect as the 'most specific' or best diagnostic test. In untreated symptomatic infants, plasma GAA (Option A) is markedly elevated and is the standard non-invasive screening tool. Furthermore, if 'specificity' is the primary criterion, *GAMT* gene sequencing (Option D) is the gold standard for a specific diagnosis, providing molecular confirmation. The rationale's claim that plasma GAA can be normal in untreated cases contradicts standard medical literature (e.g., GeneReviews), and the emphasis on CSF suggests a confusion with Creatine Transporter Deficiency (SLC6A8), where systemic markers are often normal and CSF/brain levels are required for diagnosis. Because a superior, standard-of-care answer exists (D for specificity, A for screening) and the key relies on flawed medical reasoning, the item is miskeyed.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-005", "question": "A 58-year-old develops progressive non-REM parasomnia, obstructive sleep apnea, bulbar dysfunction, and gait ataxia over 18 months. CSF shows mild lymphocytic pleocytosis. Which antibody and pathological finding are most characteristic?", "options": ["Anti-Hu; neuronal nuclear inclusions", "Anti-NMDA receptor; perivascular lymphocytic cuffing", "Anti-IgLON5; tau deposition in brainstem and hypothalamus", "Anti-LGI1; faciobrachial dystonic seizures", "Anti-GAD65; cerebellar Purkinje cell loss"], "answer": "C", "answer_index": 2, "explanation": "Anti-IgLON5 disease presents with sleep dysfunction (non-REM parasomnia, obstructive apnea) and bulbar symptoms, distinct from other autoimmune encephalitides. Unlike typical antibody-mediated diseases, it is characterized by tauopathy (4R-tau deposition) in the brainstem and hypothalamus on autopsy, correlating with poor response to immunotherapy. Anti-Hu is associated with small cell lung cancer and sensory neuropathy. Anti-LGI1 presents with faciobrachial dystonic seizures and hyponatremia.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The vignette describes the classic clinical phenotype of anti-IgLON5 disease: a distinct syndrome characterized by non-REM parasomnias, obstructive sleep apnea (often with stridor), bulbar dysfunction, and gait instability. This condition is unique because, despite the presence of cell-surface antibodies, the underlying pathology is a neurodegenerative tauopathy involving the brainstem and hypothalamus. Option C correctly identifies both the antibody (Anti-IgLON5) and the hallmark pathological finding (tau deposition). The other options refer to different autoimmune or paraneoplastic syndromes: Anti-Hu (sensory neuronopathy/limbic encephalitis), Anti-NMDA (psychiatric/dyskinesias), Anti-LGI1 (faciobrachial dystonic seizures), and Anti-GAD65 (stiff person syndrome/ataxia), none of which fit the specific sleep-predominant presentation described. The item is medically accurate, logically sound, and tests a high-yield, specific association.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The vignette describes the classic clinical phenotype of anti-IgLON5 disease: a distinct syndrome characterized by non-REM parasomnias, obstructive sleep apnea (often with stridor), bulbar dysfunction, and gait instability. This condition is unique because, despite the presence of cell-surface antibodies, the underlying pathology is a neurodegenerative tauopathy involving the brainstem and hypothalamus. Option C correctly identifies both the antibody (Anti-IgLON5) and the hallmark pathological finding (tau deposition). The other options refer to different autoimmune or paraneoplastic syndromes: Anti-Hu (sensory neuronopathy/limbic encephalitis), Anti-NMDA (psychiatric/dyskinesias), Anti-LGI1 (faciobrachial dystonic seizures), and Anti-GAD65 (stiff person syndrome/ataxia), none of which fit the specific sleep-predominant presentation described. The item is medically accurate, logically sound, and tests a high-yield, specific association.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-006", "question": "During VV-ECMO for severe ARDS, the circuit suddenly shows extensive air with the patient becoming pulseless. What is the immediate management step?", "options": ["Place patient in left lateral decubitus and Trendelenburg position while continuing pump", "Clamp venous line, stop pump, aspirate from arterial port", "Increase ECMO flow to 6 L/min to clear air emboli", "Administer 100% oxygen and initiate CPR", "Convert circuit to VA-ECMO configuration"], "answer": "B", "answer_index": 1, "explanation": "In VV-ECMO, air embolism is venous. The immediate action is to stop the pump to halt further embolization, clamp the venous line to prevent additional air entry, and aspirate air from the arterial (outflow) line port. Durant's position is ineffective for venous emboli. Increasing pump flow worsens embolization. CPR is secondary to circuit management. Configuration change does not address the acute air emergency.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical scenario describes a massive air embolism in the ECMO circuit resulting in cardiac arrest. The immediate and absolute priority is to stop the administration of air to the patient. Options A and C are lethal because they involve continuing or increasing pump flow, which would pump more air into the patient. Option E (changing configuration) does not address the acute air embolus. Option D (CPR) is necessary for pulselessness, but resuscitation will fail if the mechanism (air pumping) is not halted first. Option B is the only choice that includes stopping the pump, making it the correct answer by elimination. However, the specific steps in B are technically suboptimal: standard protocol is to clamp the return (arterial) line first or simultaneously to prevent air entry, whereas clamping the venous (drainage) line first while the pump is spinning can cause cavitation or de-priming. Additionally, the author's rationale incorrectly states that Durant's position is ineffective for venous emboli (it is the standard maneuver for VAE), though Option A is incorrect regardless due to 'continuing pump'. Despite these nuances, B is the only defensible 'best' answer.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical scenario describes a massive air embolism in the ECMO circuit resulting in cardiac arrest. The immediate and absolute priority is to stop the administration of air to the patient. Options A and C are lethal because they involve continuing or increasing pump flow, which would pump more air into the patient. Option E (changing configuration) does not address the acute air embolus. Option D (CPR) is necessary for pulselessness, but resuscitation will fail if the mechanism (air pumping) is not halted first. Option B is the only choice that includes stopping the pump, making it the correct answer by elimination. However, the specific steps in B are technically suboptimal: standard protocol is to clamp the return (arterial) line first or simultaneously to prevent air entry, whereas clamping the venous (drainage) line first while the pump is spinning can cause cavitation or de-priming. Additionally, the author's rationale incorrectly states that Durant's position is ineffective for venous emboli (it is the standard maneuver for VAE), though Option A is incorrect regardless due to 'continuing pump'. Despite these nuances, B is the only defensible 'best' answer.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-007", "question": "A 22-year-old with relapsed ALL receives axicabtagene ciloleucel. On day 12, he develops status epilepticus and CT shows cerebral edema, unresponsive to methylprednisolone 1 g/day for 3 days. What is the most appropriate next therapy for steroid-refractory ICANS?", "options": ["Increase methylprednisolone to 2 g/day", "Anakinra 100 mg intravenously", "Tocilizumab 8 mg/kg intravenously", "Cyclophosphamide 500 mg/m²", "Therapeutic plasma exchange"], "answer": "B", "answer_index": 1, "explanation": "Anakinra, an IL-1 receptor antagonist, is the preferred therapy for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). Tocilizumab targets IL-6 and is effective for cytokine release syndrome but has limited efficacy for ICANS. Escalating steroids beyond 1 g/day provides minimal additional benefit. Cyclophosphamide is not used for ICANS. Plasma exchange would eliminate the therapeutic CAR-T cells.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V (Valid). Verdict on keyed answer: Correct best. The vignette describes a patient with Grade 4 ICANS (status epilepticus, cerebral edema) following CD19 CAR T-cell therapy, which is refractory to high-dose corticosteroids (methylprednisolone 1 g/day). Current consensus guidelines (e.g., ASCO, NCCN, SITC) recommend Anakinra (an IL-1 receptor antagonist) as the standard next-line therapy for steroid-refractory ICANS. Tocilizumab is indicated for Cytokine Release Syndrome (CRS) but has poor blood-brain barrier penetration and may transiently worsen ICANS by increasing serum IL-6; it is not the treatment for isolated ICANS. Increasing steroids beyond pulse doses (1 g/day) provides little benefit. Cyclophosphamide is not indicated for acute neurotoxicity management. Plasma exchange is a last-resort salvage therapy that removes the therapeutic cells, used only when pharmacologic interventions fail. While the vignette cites 'axicabtagene ciloleucel' for ALL (which is technically off-label/incorrect as Brexucabtagene autoleucel or Tisagenlecleucel are approved for ALL, while Axi-cel is for lymphoma), the toxicity management logic remains identical and the error does not affect the correct answer.\",\"medical_accuracy_score\":\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V (Valid). Verdict on keyed answer: Correct best. The vignette describes a patient with Grade 4 ICANS (status epilepticus, cerebral edema) following CD19 CAR T-cell therapy, which is refractory to high-dose corticosteroids (methylprednisolone 1 g/day). Current consensus guidelines (e.g., ASCO, NCCN, SITC) recommend Anakinra (an IL-1 receptor antagonist) as the standard next-line therapy for steroid-refractory ICANS. Tocilizumab is indicated for Cytokine Release Syndrome (CRS) but has poor blood-brain barrier penetration and may transiently worsen ICANS by increasing serum IL-6; it is not the treatment for isolated ICANS. Increasing steroids beyond pulse doses (1 g/day) provides little benefit. Cyclophosphamide is not indicated for acute neurotoxicity management. Plasma exchange is a last-resort salvage therapy that removes the therapeutic cells, used only when pharmacologic interventions fail. While the vignette cites 'axicabtagene ciloleucel' for ALL (which is technically off-label/incorrect as Brexucabtagene autoleucel or Tisagenlecleucel are approved for ALL, while Axi-cel is for lymphoma), the toxicity management logic remains identical and the error does not affect the correct answer.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-008", "question": "A 35-year-old presents with refractory shock (BP 70/40) and bradycardia (HR 40) after ingesting 10 g of sustained-release verapamil. High-dose insulin euglycemic therapy (HIET) is initiated. What is the optimal insulin dosing and monitoring frequency?", "options": ["0.5-1 unit/kg/hr; check glucose every 2 hours", "1-10 units/kg/hr; check glucose every hour", "0.1-0.5 units/kg/hr; check potassium every 4 hours", "5-20 units/kg/hr; check lactate every 2 hours", "2-5 units/kg/hr; check pH every 4 hours"], "answer": "B", "answer_index": 1, "explanation": "HIET for severe calcium channel blocker overdose requires supraphysiologic insulin doses of 1-10 units/kg/hr to overcome insulin resistance and maximize myocardial glucose uptake. Blood glucose must be monitored hourly to maintain euglycemia (150-200 mg/dL) with concurrent dextrose infusion. Lower doses are ineffective. Doses exceeding 10 units/kg/hr are not standard practice. Potassium and pH are monitored but glucose is the critical parameter.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette describes severe calcium channel blocker toxicity (verapamil) with refractory shock, correctly identifying High-dose Insulin Euglycemic Therapy (HIET) as the intervention. The question tests knowledge of the specific supraphysiologic dosing and safety monitoring required for HIET. Standard toxicology guidelines (e.g., Goldfrank's, UpToDate) recommend initiating insulin at 1 unit/kg/hr and titrating up to 10 units/kg/hr to overcome calcium channel blockade-induced hypoinsulinemia and improve myocardial contractility. Glucose monitoring is the critical safety step, typically required every 30–60 minutes to manage the high risk of hypoglycemia. Option B correctly identifies the therapeutic dose range (1–10 units/kg/hr) and the appropriate monitoring parameter and frequency (glucose q1h). Options A and C suggest doses that are too low (similar to DKA management) and ineffective for inotropy. Options D and E prioritize incorrect monitoring parameters (lactate, pH) over glucose. The item is medically accurate, logically sound, and has a unique best answer.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette describes severe calcium channel blocker toxicity (verapamil) with refractory shock, correctly identifying High-dose Insulin Euglycemic Therapy (HIET) as the intervention. The question tests knowledge of the specific supraphysiologic dosing and safety monitoring required for HIET. Standard toxicology guidelines (e.g., Goldfrank's, UpToDate) recommend initiating insulin at 1 unit/kg/hr and titrating up to 10 units/kg/hr to overcome calcium channel blockade-induced hypoinsulinemia and improve myocardial contractility. Glucose monitoring is the critical safety step, typically required every 30–60 minutes to manage the high risk of hypoglycemia. Option B correctly identifies the therapeutic dose range (1–10 units/kg/hr) and the appropriate monitoring parameter and frequency (glucose q1h). Options A and C suggest doses that are too low (similar to DKA management) and ineffective for inotropy. Options D and E prioritize incorrect monitoring parameters (lactate, pH) over glucose. The item is medically accurate, logically sound, and has a unique best answer.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-009", "question": "A 6-month-old male infant presents with severe eczema, petechiae, recurrent otitis media, and platelet count of 30,000/µL with small platelet volume. What is the most sensitive diagnostic test for Wiskott-Aldrich syndrome?", "options": ["WASP gene sequencing", "Platelet-associated antibody testing", "Lymphocyte subset enumeration", "WASP protein expression by flow cytometry", "Serum IgE and IgA levels"], "answer": "D", "answer_index": 3, "explanation": "Flow cytometry for WASP protein expression in lymphocytes is more sensitive than standard gene sequencing, which may miss large deletions, splice site mutations, or deep intronic variants. Absent or reduced WASP protein expression confirms the diagnosis. Platelet antibodies are negative. Lymphocyte subsets are variable. IgE is elevated and IgA is low but these are nonspecific.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"The clinical vignette correctly describes the classic triad of Wiskott-Aldrich syndrome (WAS): eczema, immunodeficiency (recurrent otitis), and microthrombocytopenia. The question asks for the \\\"most sensitive diagnostic test.\\\" The keyed answer is D (Flow cytometry), with a rationale arguing it detects cases (like large deletions) that standard sequencing might miss. However, this logic is medically flawed and outdated. \\n\\n1) **Gold Standard:** *WAS* gene sequencing (Option A) is the definitive confirmatory diagnostic test. Modern genetic testing includes deletion/duplication analysis, overcoming the limitations cited in the rationale.\\n2) **Sensitivity:** While flow cytometry is an excellent *screening* tool, it can produce false negatives in patients who express non-functional protein (e.g., certain missense mutations found in X-linked thrombocytopenia or milder WAS). Genetic sequencing detects these variants. As the reference standard, sequencing is superior in both sensitivity and specificity.\\n3) **Distinction:** Medical consensus classifies flow cytometry as a \\\"screen\\\" and sequencing as the \\\"diagnosis.\\\" \\n\\nBecause Option A represents the gold standard and is more sensitive than D across the full spectrum of WAS phenotypes (including those with normal protein levels), the item is miskeyed. The rationale relies on a technical limitation of older sequencing methods that does not apply to current best practices.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":false,\"logical_false_reason\":\"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "The clinical vignette correctly describes the classic triad of Wiskott-Aldrich syndrome (WAS): eczema, immunodeficiency (recurrent otitis), and microthrombocytopenia. The question asks for the \"most sensitive diagnostic test.\" The keyed answer is D (Flow cytometry), with a rationale arguing it detects cases (like large deletions) that standard sequencing might miss. However, this logic is medically flawed and outdated. \n\n1) **Gold Standard:** *WAS* gene sequencing (Option A) is the definitive confirmatory diagnostic test. Modern genetic testing includes deletion/duplication analysis, overcoming the limitations cited in the rationale.\n2) **Sensitivity:** While flow cytometry is an excellent *screening* tool, it can produce false negatives in patients who express non-functional protein (e.g., certain missense mutations found in X-linked thrombocytopenia or milder WAS). Genetic sequencing detects these variants. As the reference standard, sequencing is superior in both sensitivity and specificity.\n3) **Distinction:** Medical consensus classifies flow cytometry as a \"screen\" and sequencing as the \"diagnosis.\" \n\nBecause Option A represents the gold standard and is more sensitive than D across the full spectrum of WAS phenotypes (including those with normal protein levels), the item is miskeyed. The rationale relies on a technical limitation of older sequencing methods that does not apply to current best practices.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed125", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed125-010", "question": "A 28-year-old develops progressive myoclonus epilepsy, cerebellar ataxia, and visual loss over 3 years. EEG shows generalized spike-wave discharges. Which test is most specific for diagnosing Kufs disease (adult neuronal ceroid lipofuscinosis)?", "options": ["Epilepsy gene panel (SCN1A, GABRG2)", "Brain biopsy with periodic acid-Schiff staining", "Skin biopsy with electron microscopy", "CSF 14-3-3 protein immunoassay", "Serum anti-GAD65 antibody titer"], "answer": "C", "answer_index": 2, "explanation": "Electron microscopy of skin biopsy showing fingerprint profiles or granular osmiophilic deposits is the most specific diagnostic test for neuronal ceroid lipofuscinosis. Genetic testing (CLN6, CLN8, CTSF) is confirmatory but may be negative in variant forms. Brain biopsy is invasive and unnecessary. CSF 14-3-3 protein is elevated in Creutzfeldt-Jakob disease. Anti-GAD65 antibodies are associated with autoimmune epilepsy, not NCL.", "generator_model": "kimi-k2-thinking", "seed": 125, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gemini-3-pro-preview", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict on keyed answer: Correct best. The vignette describes a patient with progressive myoclonus epilepsy (PME), ataxia, and visual loss, consistent with Neuronal Ceroid Lipofuscinosis (NCL). While the specific label 'Kufs disease' (Adult NCL) is classically defined by the absence of visual loss (distinguishing it from juvenile forms), the core clinical picture and question intent clearly target the NCL category. Among the options, Skin Biopsy with Electron Microscopy (C) is the classic diagnostic test for NCL, revealing specific ultrastructural findings (fingerprint profiles, granular osmiophilic deposits). Option A is incorrect because the genes listed (SCN1A, GABRG2) are associated with Dravet syndrome and GEFS+, not NCL. Options D and E refer to Creutzfeldt-Jakob disease and autoimmune epilepsy/Stiff Person Syndrome, respectively. Although modern workup often starts with broad genetic panels, the specific genetic option provided is irrelevant, making C the only medically correct choice for NCL diagnosis. The item is logically valid, though the inclusion of 'visual loss' in a Kufs disease vignette is a minor medical inaccuracy.\",\"medical_accuracy_score\":\"3\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. The vignette describes a patient with progressive myoclonus epilepsy (PME), ataxia, and visual loss, consistent with Neuronal Ceroid Lipofuscinosis (NCL). While the specific label 'Kufs disease' (Adult NCL) is classically defined by the absence of visual loss (distinguishing it from juvenile forms), the core clinical picture and question intent clearly target the NCL category. Among the options, Skin Biopsy with Electron Microscopy (C) is the classic diagnostic test for NCL, revealing specific ultrastructural findings (fingerprint profiles, granular osmiophilic deposits). Option A is incorrect because the genes listed (SCN1A, GABRG2) are associated with Dravet syndrome and GEFS+, not NCL. Options D and E refer to Creutzfeldt-Jakob disease and autoimmune epilepsy/Stiff Person Syndrome, respectively. Although modern workup often starts with broad genetic panels, the specific genetic option provided is irrelevant, making C the only medically correct choice for NCL diagnosis. The item is logically valid, though the inclusion of 'visual loss' in a Kufs disease vignette is a minor medical inaccuracy.", "medical_accuracy_score": 3, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 3}]